GST Council Extends Concessional Rates On COVID-Related Medicines Till Dec 31

Lucknow : The GST Council on Friday extended Goods and Services Tax concessions on COVID-related medicines till December 31 this year.

She said extension has been given in existing concessional GST rates on COVID-19 treatment drugs up to December 31. The exemption was valid till September 30.
These drugs are Amphotericin B (Nil), Remdesivir ( 5 %), Tocilizumab (Nil) and anti-coagulants like Heparin – (5 %).

GST rates on 7 other medicines recommended by Department of Pharmaceuticals reduced from 12% to 5% till 31st December 2021, namely-Itolizumab, Posaconazole, Infliximab, Favipiravir, Casirivimab & Imdevimab, 2-Deoxy-D-Glucose and Bamlanivimab & Etesevimab.

GST rates on Retro fitment kits for vehicles used by persons with special abilities reduced to 5%.

The minister spoke about tax concessions on medicines not related to COVID-19.

“We have seen in the last one year and probably earlier that some life-saving drugs, which are not connected with Corona and are very expensive. Exemptions have been given for such drugs. I am giving the names of two because those two are very expensive drugs — Zolgensma and Viltepso. These two are very important drugs which cost something like Rs 16 crores. So the council has decided to grant exemption from GST for these two for personal use,” she said.

“Drugs that are suggested by the Ministry of Health for treating muscular atrophy, on the recommendation of Health Ministry and Department of Pharmaceuticals, are also exempted for IGST on import for personal use. The concessional GST rates on corona-related medicines have been extended till December 31, 2021. ” she added.

Sitharaman said that cancer-related drugs – Keytruda – along with similar other medicines used in the treatment of cancer as per the Health Ministry are being recommended for tax concession from 12 to 5 per cent.

  • Related Posts

    • Pharma
    • July 8, 2025
    • 47 views
    HC-ordered expert panel for weight loss drug may be set up by mid-July

    The Central Drugs Standard Control Organization (CDSCO) is likely to begin work on forming a court-ordered expert panel to study the unregulated use of weight loss drugs by mid-July, according…

    • Pharma
    • July 8, 2025
    • 30 views
    Biocon Biologics Gets UK Nod for Vevzuo, Evfraxy

    New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for Vevzuo…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    HC-ordered expert panel for weight loss drug may be set up by mid-July

    HC-ordered expert panel for weight loss drug may be set up by mid-July

    Biocon Biologics Gets UK Nod for Vevzuo, Evfraxy

    Biocon Biologics Gets UK Nod for Vevzuo, Evfraxy

    Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

    Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

    ‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare

    ‘AACI Came, AACI Saw, AACI Conquered’ Indian Accreditation Domain in Healthcare